Format

Send to

Choose Destination
Aktuelle Urol. 2011 Jul;42(4):242-6. doi: 10.1055/s-0031-1271548. Epub 2011 Jun 30.

[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].

[Article in German]

Author information

1
Klinik für Urologie, Charité - Universitätsmedizin Berlin, Germany. Kurt.miller@charite.de

Abstract

With the introduction of targeted drug therapies, a paradigm shift for the treatment of metastatic renal cell carcinoma has taken place. New compounds like sunitinib, sorafenib, bevacizumab and temsirolimus have become established as new therapeutic standards to replace the use of cytokines as standard therapy. Recently, these substances have been complemented by everolimus and pazopanib. An interdisciplinary consensus conference was held to discuss which criteria to consider when using these drugs (treatment sequence) and what questions remain unanswered based on the current study situation (open questions). Results from the 2009 conference provided the basis for the 2010 meeting. The results of the 2010 conference are presented as short theses.

PMID:
21720974
DOI:
10.1055/s-0031-1271548
[Indexed for MEDLINE]

Publication type, MeSH terms, Substances

Publication type

MeSH terms

Substances

Supplemental Content

Full text links

Icon for Georg Thieme Verlag Stuttgart, New York
Loading ...
Support Center